Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Despite numerous advances in treatment options, advanced gastric cancer (AGC) remains a major public health issue and the leading cause of cancer-related deaths. Cisplatin is one of the most effective broad-spectrum anticancer drugs for AGC and a doublet combination regimen of either cisplatin-based or 5-fluorouracil (5FU)-based chemotherapy is generally used for treatment of patients with AGC. However, there is still no consensus on the best regimen for treating AGC. Recently, various new chemotherapeutic agents, including oral 5FU, taxanes, and irinotecan, have been identified as improving the outcomes for AGC when used as a single agent or in combination with non-platinum chemotherapy. Nonetheless, it is still unclear whether non-platinum-based chemotherapy is a viable treatment option for patients with AGC. Accordingly, this review focuses on the efficacy and tolerability of non-platinum-based chemotherapy for patients with AGC.
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
Byung Woog
BW
Kang
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
Jong Gwang
JG
Kim
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
Oh-Kyoung
OK
Kwon
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
Ho Young
HY
Chung
Byung Woog Kang, Jong Gwang Kim, Department of Hematology/Oncology, Kyungpook National University Medical Center, Daegu 702-210, South Korea.
Wansik
W
Yu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D018579:Patient Selection; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D043823:Taxoids; D000077146:Irinotecan; D005472:Fluorouracil; D002166:Camptothecin
5-fluorouracil; Cisplatin; Gastric cancer; Irinotecan; Taxane